Impact of new DAA therapy on real clinical practice: a multicenter region-wide cohort study.
Simone LaniniPaola ScognamiglioAlessandra MecozziLorella LombardozziVincenzo VulloMario AngelicoAntonio GasbarriniGloria TalianiAdolfo Francesco AttiliCarlo Federico PernoAdriano De SantisVincenzo PuroFabio CerquaGianpiero D'OffiziAdriano PellicelliOrlando ArmignaccoFrancesco Saverio MenniniMassimo SicilianoEnrico GirardiVincenzo PanellaGiuseppe Ippolitonull nullPublished in: BMC infectious diseases (2018)
Our study confirmed the extraordinary efficacy of DAAs outside clinical trials. The advantage of DAAs was particularly significant for those patients who were previously considered as difficult-to-treat and did not have treatment options before DAAs era. Intervention based on network of select centers and prioritization of patients according to diseases severity was successful. Further studies are needed to establish whether clearance of HCV after DAAs therapy can arrest or even revert liver fibrosis in non-cirrhotic patients and/or improve life quality and expectancy in those who achieve SVR12 with cirrhosis.
Keyphrases
- clinical trial
- newly diagnosed
- ejection fraction
- liver fibrosis
- clinical practice
- prognostic factors
- randomized controlled trial
- stem cells
- hepatitis c virus
- chronic kidney disease
- mesenchymal stem cells
- cross sectional
- bone marrow
- patient reported outcomes
- study protocol
- hiv infected
- phase ii
- replacement therapy
- patient reported
- antiretroviral therapy
- phase iii